FARMINTERPRAISEZ, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Phase 2

Not yet recruiting

Conditions: Cystitis

Interventions: Drug: XC243 50 mg
Drug: Placebo
Drug: XC243 25 mg
Drug: XC243 75 mg

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 280

Registration Number: NCT06391164

Locations: 🇷🇺
LLC "Clinic Zvezdnaya", Saint Petersburg, Russian Federation
🇷🇺
St. Petersburg State Budgetary Healthcare Institution "City Polyclinic № 112", Saint Petersburg, Russian Federation
🇷🇺
LLC "Research Center Eco-Safety", Saint Petersburg, Russian Federation

and more 4 locations

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo single
Drug: XC243 200 mg multiple
Drug: XC243 100 mg single
Drug: XC243 200 mg single-dose food effect
Drug: Placebo single-dose food effect
Drug: Placebo multiple
Drug: XC243 50 mg single

First Posted Date: 2022-11-28

Last Posted Date: 2023-11-18

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 38

Registration Number: NCT05628116

Locations: 🇷🇺
LLS X7 Clinical Research, Saint Petersburg, Russian Federation

Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19

Phase 2

Conditions: SARS-CoV-2 Infection
Lung Fibrosis

Interventions: Drug: Placebo
Drug: Treamid twice a day
Drug: Treamid once a day
Drug: Treamid

First Posted Date: 2022-08-25

Last Posted Date: 2022-08-25

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 412

Registration Number: NCT05516550

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia

Phase 2

Completed

Conditions: Fibrosis Lung
SARS-CoV-2 Infection

Interventions: Drug: Placebo
Drug: Treamid

First Posted Date: 2020-08-26

Last Posted Date: 2021-04-05

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 60

Registration Number: NCT04527354

Locations: 🇷🇺
Federal State-Funded Research Institution "Research Institute of Complex Cardiovascular Diseases", Kemerovo, Russian Federation
🇷🇺
Federal State Budgetary Institution "N.N. Burdenko Military Clinical Hospital", Moscow, Russian Federation
🇷🇺
SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation

and more 5 locations

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

Phase 1

Completed

Conditions: Metabolic Syndrome

Interventions: Drug: Treamid 15 mg
Drug: Placebo
Drug: Treamid 5 mg
Drug: Treamid 50 mg

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-17

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 20

Registration Number: NCT04428593

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Phase 2

Completed

Conditions: Influenza
Acute Respiratory Viral Infections

Interventions: Drug: Placebo
Drug: XC221

First Posted Date: 2019-02-05

Last Posted Date: 2020-11-16

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 120

Registration Number: NCT03830905

Locations: 🇷🇺
Non-governmental Healthcare Institution "N.A.Semashko Road Clinical Hospital at the Lyublino station of the open joint-stock company "Russian Railways", Moscow, Russian Federation
🇷🇺
Federal State Budgetary Institution of Health "Northern Medical Clinical Center named after NA Semashko of the Federal Medical and Biological Agency", Arkhangelsk, Russian Federation
🇷🇺
Regional State Budgetary Institution of Health "Belgorod Regional Clinical Hospital of St. Joasaph", Belgorod, Russian Federation

and more 13 locations

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Phase 1

Completed

Conditions: Influenza
Acute Respiratory Infection

Interventions: Drug: XC221 60 mg
Drug: Placebo
Drug: XC221 200 mg

First Posted Date: 2018-03-08

Last Posted Date: 2018-03-08

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 32

Registration Number: NCT03459391

Locations: 🇷🇺
SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

Phase 2

Completed

Conditions: Acute Respiratory Viral Infections
Influenza

Interventions: Drug: XC221 100 mg
Drug: XC221 200 mg
Drug: Placebo

First Posted Date: 2018-03-06

Last Posted Date: 2019-11-04

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 120

Registration Number: NCT03455491

Locations: 🇷🇺
The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation, Saint Petersburg, Russian Federation
🇷🇺
Research Institute of Influenza, Saint Petersburg, Russian Federation
🇷🇺
City Clinical Hospital №40 of Kurortny District, Saint Petersburg, Russian Federation

and more 8 locations

XC8 in the Treatment of Patients With Bronchial Asthma

Phase 2

Completed

Conditions: Bronchial Asthma

Interventions: Drug: XC8 Oral Tablet
Drug: Placebo Oral Tablet

First Posted Date: 2018-03-01

Last Posted Date: 2018-03-01

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 120

Registration Number: NCT03450434

Locations: 🇷🇺
"Allergy and Immunology Center" LLC, Krasnodar, Russian Federation
🇷🇺
"Pulmonology Research Institute" FMBA of Russia, Moscow, Russian Federation
🇷🇺
Central Research Institute for Tuberculosis at Russian Medical Sciences, Moscow, Russian Federation

and more 9 locations

XC8 in the Treatment of Patients With Acute Respiratory Viral Infection

Phase 2

Completed

Conditions: Acute Respiratory Infection
Influenza

Interventions: Drug: XC8 100 mg
Drug: XC8 20 mg
Drug: XC8 200 mg
Drug: Placebo

First Posted Date: 2018-02-22

Last Posted Date: 2018-02-23

Lead Sponsor: PHARMENTERPRISES LLC

Target Recruit Count: 320

Registration Number: NCT03441373

Locations: 🇷🇺
Federal State Budgetary institution "Diagnostic center with polyclinics" of the Administrative Department of the President of the Russian Federation, Saint Petersburg, Russian Federation
🇷🇺
State Budgetary Healthcare Institution (SBHI) of Yaroslavl region, Yaroslavl, Russian Federation
🇷🇺
Nizhegorodsky region SBHI Nizhniy Novgorod Infectious Regional Clinical Hospital № 2, Nizhny Novgorod, Russian Federation

and more 15 locations

Home Terms & Conditions Privacy Policy